We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

By LabMedica International staff writers
Posted on 14 Jun 2024
Print article
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study of Liver Diseases (AASLD) recommends these high-risk patients undergo surveillance every six months. Regular testing is crucial for early cancer detection, which significantly increases the likelihood of successful treatment. Common causes of cirrhosis, a leading risk factor for HCC, include Hepatitis B, Hepatitis C, excessive alcohol consumption, obesity, diabetes, and nonalcoholic fatty liver disease (NAFLD). Although ultrasound is the standard method for liver surveillance, it is often considered insufficient by many physicians due to performance issues and patient accessibility barriers. Now, a reliable and accessible approach using a simple blood draw has been validated in a clinical trial with promising results.

The HelioLiver Dx test, developed by Helio Genomics (Irvine, CA, USA) and powered by artificial intelligence (AI), analyzes cell-free DNA (cfDNA) methylation patterns, serum protein biomarkers, and patient demographic data to detect HCC in cirrhotic patients who require biannual surveillance as per AASLD guidelines. Helio’s innovative algorithm identifies specific methylation patterns indicative of cancer and searches for proteins typically elevated in HCC cases. The CLiMB study, which included 1,968 subjects at high risk for liver cancer, represents the largest completed prospective, multi-center clinical trial for a liver cancer detection liquid biopsy in the United States. The study primarily aimed to compare the sensitivity and specificity of the HelioLiver Dx test with that of ultrasound in detecting HCC among patients predisposed to the disease due to liver cirrhosis.

Participants in the study were diagnosed with liver cirrhosis through various methods including blood analytes, ultrasound, elastography, diagnostic imaging via CT or MRI (as indicated in radiology reports), or liver biopsy (as indicated in pathology reports). They were deemed eligible for HCC surveillance by their physicians. The results from the CLiMB study revealed that the HelioLiver Dx test not only demonstrated greater sensitivity than ultrasound in detecting overall HCC lesions but also showed better performance in identifying early-stage and small lesions across a diverse patient group with liver cirrhosis. The HelioLiver Dx test achieved the prespecified coprimary endpoints, showing superior sensitivity and non-inferior specificity compared to ultrasound in the detection of HCC lesions. Additionally, it met a secondary endpoint by exhibiting superior sensitivity in detecting HCC lesions up to 4 cm in diameter. Overall, the HelioLiver Dx test outperformed ultrasound in terms of sensitivity in detecting HCC lesions among cirrhotic patients.

"The results from our CLiMB study clearly demonstrate that the HelioLiver Dx test passed endpoints and demonstrated superior sensitivity and non-inferior specificity compared to ultrasound in a real world setting,” added Justin Chen Li, Chief Executive Officer, Helio Genomics. “We believe our blood-based test can address many barriers to care and socioeconomic inequities that exist today, leading to better patient outcomes and ultimately saving more lives.”

Related Links:
Helio Genomics

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Malaria Rapid Test
ASSURE Malaria P.f/P.v Rapid Test
New
Male Fertility Rapid Test
SP-10

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.